This is an observation study to find out the ‘real world’ effectiveness (cure) of AbbVie’s Viekira Pak (with and without ribavirin) in genotype 1 and 4 patients. This includes treatment-naïve and treatment experienced patients. AbbVie’s drug combinations are approved by the Food and Drug Administration (FDA) to treat hepatitis C genotype 1 (cure rates = 95 to 100%) and genotype 4 (cure rates = 91 to 100%).
France: The Effectiveness of Paritaprevir/r – Ombitasvir, ± Dasabuvir, ± Ribavirin in France (OPALE)
To view the entire study description, click here